Clinical trial
Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
NCT00313391 · Emory University, Other · Completed
Key facts
| NCT number | NCT00313391 |
|---|---|
| Title | Risperdal Consta and Health Care Utilization in Patients With Schizophrenia |
| Official title | The Effects of Risperdal Consta on Health Care Utilization Costs in Chronically Ill Schizophrenic Patients |
| Lead sponsor | Emory University, Other |
| Collaborators | Janssen, L.P. - Investigator Initiated Studies Program |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Risperdal Consta |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2007 |
| First posted | Apr 12, 2006 |
| Last update posted | Sep 25, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: